{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113762.1.4.1116.388",
  "meta" : {
    "versionId" : "4",
    "lastUpdated" : "2023-12-21T17:43:03.000-05:00",
    "profile" : [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueString" : "CancerLinQ Author"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate" : "2024-06-03"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate" : "2017-11-29"
    }
  ],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.388",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113762.1.4.1116.388"
    }
  ],
  "version" : "20171129",
  "name" : "NoAdjuvantHormonalTherapyProstate",
  "title" : "No Adjuvant Hormonal Therapy Prostate",
  "status" : "retired",
  "experimental" : false,
  "date" : "2017-11-29T01:00:05-05:00",
  "publisher" : "CancerLinQ Steward",
  "jurisdiction" : [
    {
      "coding" : [
        {
          "system" : "urn:iso:std:iso:3166",
          "code" : "US"
        }
      ]
    }
  ],
  "purpose" : "(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: )",
  "compose" : {
    "include" : [
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "concept" : [
          {
            "code" : "1P",
            "display" : "Performance Measure Exclusion Modifier due to Medical Reasons"
          },
          {
            "code" : "2P",
            "display" : "Performance Measure Exclusion Modifier due to Patient Reasons"
          },
          {
            "code" : "4164F",
            "display" : "Adjuvant (ie, in combination with external beam radiotherapy to the prostate for prostate cancer) hormonal therapy (gonadotropin-releasing hormone [GnRH] agonist or antagonist) prescribed/administered (PRCA)"
          }
        ]
      }
    ]
  },
  "expansion" : {
    "identifier" : "urn:uuid:a4742af5-09d2-4064-913c-95a8b57d5f51",
    "timestamp" : "2024-06-14T11:28:04-04:00",
    "total" : 3,
    "contains" : [
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "1P",
        "display" : "Performance Measure Exclusion Modifier due to Medical Reasons"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "2P",
        "display" : "Performance Measure Exclusion Modifier due to Patient Reasons"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "4164F",
        "display" : "Adjuvant (ie, in combination with external beam radiotherapy to the prostate for prostate cancer) hormonal therapy (gonadotropin-releasing hormone [GnRH] agonist or antagonist) prescribed/administered (PRCA)"
      }
    ]
  }
}
